adalimumab sold brand name humira among others monoclonal antibody used treat rheumatoid arthritis psoriatic arthritis ankylosing spondylitis crohns disease ulcerative colitis plaque psoriasis hidradenitis suppurativa uveitis juvenile idiopathic administered subcutaneous injection injection common side effects include upper respiratory tract infections pain site injection rash side effects may include serious infections cancer anaphylaxis reactivation hepatitis b new onset exacerbation demyelinating diseases multiple sclerosis heart failure liver failure aplastic use pregnancy recommended sources show use breastfeeding may adalimumab diseasemodifying antirheumatic drug monoclonal antibody works inactivating tumor necrosis factoralpha adalimumab approved medical use united states world health organizations list essential available biosimilar commonly prescribed medication united states million us adalimumab indicated treatment rheumatoid arthritis juvenile idiopathic arthritis psoriatic arthritis ankylosing spondylitis adult crohns disease pediatric crohns disease ulcerative colitis plaque psoriasis hidradenitis suppurativa eu indicated treatment adalimumab shown reduce signs symptoms moderate severe rheumatoid arthritis adults may used alone combination diseasemodifying antirheumatic also shown efficacy moderate severe polyarticular juvenile idiopathic arthritis children four years older indicated treatment condition rheumatoid arthritis indicated use alone methotrexate similar medicines united states since similar effectiveness methotrexate combination nearly doubles response rate methotrexate adalimumab shown reduce signs symptoms approved treatment ankylosing spondylitis adalimumab shown reduce signs symptoms moderate severe crohns approved use uk since adalimumab may effective well tolerated ulcerative colitis approved us food drug administration fda treatment moderate severe cases adalimumab shown treat moderate severe chronic plaque psoriasis adults condition many areas body may benefit taking injections pills systemic therapy phototherapy treatment using ultraviolet light alone adalimumab shown effective therapy used either continuously intermittently patients moderate severe adalimumab approved hidradenitis suppurativa adalimumab shown reduce signs symptoms moderate severe polyarticular juvenile idiopathic arthritis children aged four years adalimumab indicated treatment noninfectious uveitis inflammation layer beneath white strong evidence adalimumab increases risk serious infections tuberculosis also reported increase risk developing various however association may reflect increased risk developing malignancies inherent conditions treated adalimumab systematic review published found increased cancer incidence rate patients chronic inflammatory disorders treated adalimumab tnf inhibitors compared possible exception nonmelanoma skin rare reports serious liver injury rare reports demyelinating central nervous system disorders rare reports cardiac us food drug administration fda issued black box warning doctors appears product labeling adalimumab tnfinhibiting drugs instructing screen monitor potential patients anaphylaxis serious allergic reactions may also injection site reactions redness pain common may occur adalimumab first fully human monoclonal antibody approved us food drug administration derived phage adalimumab discovered result collaboration basf bioresearch corporation cambridge antibody technology uk collaboration governmentfunded medical research council three academics began initially named manufactured basf bioresearch corporation developed basf knoll basf pharma ultimately manufactured marketed abbott laboratories abbotts acquisition basf pharma january abbott split two companies one retaining abbott name named result abbvie took development marketing brand name humira stands human monoclonal antibody rheumatoid arthritis named one abbotts employees richard j karwoski also responsible leading effort get humira approved fda third tnf inhibitor infliximab etanercept approved united constructed fully human monoclonal antibody infliximab mousehuman chimeric antibody etanercept tnf receptorigg fusion proteinmedical citation needed drug candidate discovered initially using cats phage display technology named key components drug found guiding selection human antibodies phage display repertoires single epitope antigen tnf ultimate clinical candidate created manufactured basf bioresearch corporation taken drug development process basf knoll development manufacturing marketing abbott laboratories abbott acquired pharmaceutical arm basf since adalimumab approved fda treatment rheumatoid arthritis psoriatic arthritis ankylosing spondylitis crohns disease moderate severe chronic psoriasis juvenile idiopathic arthritis although approved ulcerative colitis late fda diseases management used several years cases responded conventional treatment standard dosing crohns diseasecitation needed adalimumab sold brand name humira approved use united states adalimumab sold brand names humira trudexa approved use european union september uk nhs listed humira amgevita hulio hyrimoz idacio imraldi biosimilars available almost free prescription updated february annual cost adalimumab costliest nhs drug expected drop biggest saving nhs history single drug us patent expired humira led list topselling pharmaceutical products billion global biosimilars manufactured several companies sold lower price patent indian drugmaker cadila healthcare declared launch first adalimumab biosimilar fifth us price generic launched brand name indian drugmaker torrent pharmaceuticals launched biosimilar adalimumab called adfrar second generic biosimilar september fda approved amgens biosimilar adalimumabatto sold brand name august fda approved german pharmaceutical company boehringer ingelheims biosimilar biosimilars approved use european union biosimilars approved use european union adalimumab biosimilars became available european union allowing national health service make recordbreaking single expensive drug used nhs hospitals costing million year october adalimumabadaz hyrimoz approved use united april approved use european union july adalimumabbwwd hadlima produced samsung bioepsis approved use however available least june availability amgens offering result negotiated intellectual property settlement november adalimumabafzb abrilada approved united biosimilar approved february biosimilar amsparity approved use european june biosimilar idacio approved use july adalimumabfkjp hulio approved use united august biosimilar cadalimab launched india cadila idacio approved medical use canada october november amgevita hulio hyrimoz approved medical use december committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product yuflyma intended treatment certain inflammatory autoimmune applicant medicinal product celltrion healthcare hungary kft approved medical use european union february january abrilada approved medical use september chmp adopted positive opinion recommending granting marketing authorization medicinal products libmyris hukyndra intended treatment certain inflammatory autoimmune applicant medicinal products stada biosimilars libmyris hukyndra approved medical use european union november december adalimumabaqvh yusimry approved medical use united december yuflyma approved medical use january simlandi approved medical use adalimumabaacf idacio approved medical use united states december january chmp recommended highconcentration hyrimoz biosimilar granted paneuropean marketing authorization indications covered reference medicine including crohns disease plaque psoriasis ulcerative colitis rheumatoid arthritis february amgens biosimilar adalimumabatto sold brand name amjevita launched adalimumabaaty yuflyma approved medical use united states may starting july humiras regulatory exclusivity lapsed number biosimilars hadlima hyrimoz cyltezo celltrion launched march cambridge antibody technology cat stated wish initiate discussions regarding applicability royalty offset provisions humira abbott laboratories high court london november trial began december justice hugh laddie ruled cat short version full statement proceedings justice laddie remarked abbott error made first royalty payment cat calculated basis net sales due calculated basis full royalty paid continued pay cat accordingly justice laddie went observe construction advanced abbott violence language agreements renders obscure makes little commercial sense reason cat wins abbott required pay cat million passed partners sum medical research council received million addition abbott asked pay mrc million five years providing humira remains market mrc also receive million sterling respect past may johnson johnsons centocor unit maker infliximab ruling billion abbott laboratories patent infringement process making however judgment overturned united states court appeals federal june class action lawsuit filed united food commercial workers local ufcw local abbvie alleging drug manufacturer used patent thicket strong maintain monopoly adalimumab dismissed northern district court dismissal affirmed seventh circuit court appeals august abbvie extensively used us patent system delay competitors entering market process commonly known filed patents humira granted abbvie sued amgen manufacturer amjevita violating patents amgen agreed delay sales allowed abbvie drive prices humira price humira went time abbvie made billion revenue immune activation dostarlimab ibalizumab httpsenwikipediaorgwikiadalimumab